VISION
restore patient's health
MISSION
rare genetic diseases such as Friedreich’s ataxia
CORE VALUES
Business for good / Accountability / Team-up
Science : Involved & Commited
We develop a Gene therapy product to re-establish the function of a defective protein in Friedreich ataxia Patients.
Biointaxis creates significant value at the early stages of product development (R&D), Pre-clinical (proof-of-concept and regulatory) and early clinical trials (Phase I/II). We aim to license the production and distribution rights to Pharma partners equipped with a reputation. Biointaxis is an academic spin-off company benefiting from extensive know-how in the identification of genes and mechanisms underlying neurodegenerative disorders. As shown in the table below our the leading candidate is a gene therapy product for the treatment of Friedreich Ataxia.
Biointaxis
Biointaxis is an academic Biotech spin-off recently created from the Health Sciences Research Institute Germans Trias i Pujol (IGTP) located in Badalona, Barcelona.
The team is led by Dr. Matilla and Dr. Sánchez both pioneers in the identification of ataxia genes and research in neurodegenerative disorders.
We are currently developing a gene therapy treatment for Friedreich´s ataxia, a rare inherited, progressive, neurodegenerative disease that typically affects teenagers and young adults. Our research shows efficacy of the treatment being able to re-establish the neurological functions in mice models of Friedreich´s ataxia.
We develop life-changing treatments for rare genetic diseases such as Friedreich’s ataxia.
Management & Advisory Board
Antoni Matilla Dueñas Ph.D.
CEO & Co Founder* Head of the Translational Functional Neurogenetics Unit of the Germans Trias i Pujol Research Institute (IGTP)
Ivelisse Sánchez Ph.D.
CSO & Co Founder* Principal Investigator and co-Director Laboratory of Functional Biology and Experimental Therapies in Neurosciences (IGTP)
Jaime Melendo
Board Member & Co Founder* 32 year expertise in Pharma and Biotech. CEO and shareholder of Gentec Pharmaceutical Group.
Daniel Pérez
Chief Financial Officer* 11 years as Finance Director in Gentec Pharmaceutical Group.
Luis Ruiz Avila Ph.D.
Senior Business Advisor* 17 years experience as CEO in Biotech.
Miguel Chillón Ph.D.
Scientific Advisor* ICREA Professor with 23 years of experience in gene therapy strategies using AAV viral vectors in vivo models of human diseases
El Ministerio de Ciencia e Innovación, dentro del Programa Estatal de Investigación Científica y Técnica y de Innovación 2017-2020, concedió ayuda al proyecto "Desarrollo de un fármaco innovador de terapia génica para el tratamiento de la Ataxia de Friedreich" liderado por BIOINTAXIS S.L. con número de expediente RTC-2019-006995-1. Este proyecto ha sido financiado por el Ministerio de Ciencia e Innovación dentro del Subprograma RETOS-COLABORACIÓN, Convocatoria 2019.
Biointaxis ha sido beneficiaria de un Proyecto NEOTEC subvencionado por el CDTI con la colaboración del Ministerio de Economía, Industria y Competitividad (MINECO). Número de expediente SNEO-20191074
El Ministerio de Ciencia, Innovación y Universidades, dentro del Proyecto Estratégico para la Recuperación y Transformación Económica para la Salud de Vanguardia (PERTE de Salud), concedió ayuda al proyecto "FRATAXAV: Terapia Génica para la Ataxia de Friedreich" liderado por BIOINTAXIS S.L. con expediente EXP 00156531 / IDI-20230057, ejecutado bajo el Plan de Recuperación, Transformación y Resiliencia (PRTR). Este proyecto ha sido financiado con el Mecanismo de Recuperación y Resiliencia (MRR) de la Unión Europea – NextGenerationEU.